-
Sherilyn Smith Encourages Women to Embrace Scars as Symbols of Resilience
-
Korea's Severe Asthma Patients Blocked from Biologics by Restrictive Reimbursement Rules
-
Belgium Signs Contract for 20 Rheinmetall Skyranger Air Defence Systems
-
Shanghai Science and Technology Museum Signs Pacts With London and Ottawa Institutions at CIIE
-
Fulcrum Metals PLC Announces Fulcrum to Increase Shareholding in Loyalist
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 10
-
New Gold IRA Investing Guide Explains How to Buy Gold in an IRA for American Consumers
-
RBI Data Reveals Divergence in Credit Card Spending and Debit Card Cash Withdrawals
-
First-time boat buyers advised to assess full ownership costs
-
Panthers expected to begin 2027 NRL season away from new stadium
-
Planning and preparation can reduce stress of interstate relocation
-
Sweet As app launches restaurant discovery platform
-
Two more arrested in Carrie Mullane suspected murder investigation
-
Phoenix Restaurants Offer Thanksgiving Dinner to Go for Pickup
-
MLA seeks inquiry into reported sectarian gestures on Ormeau Road
-
Mayo school appeals for information after convent and chapel vandalism
-
Louise O’Reilly attacks Simon Harris over unemployment remarks
-
Virginia overwhelms Arkansas 91-72 behind balanced scoring
-
Canadian soldier Aidan Goulding remembered at Vancouver funeral
-
Second major storm brings destructive winds and outages to British Columbia
-
Tayyab Arif hits 57 on Pakistan Test debut against Sri Lanka
-
Godzilla Minus Zero leads North American box office with $31.6m
-
Robert Trujillo discusses literacy and social justice children’s books
-
Advocate calls for coordinated support for children facing trafficking
-
Civil rights advocate William Bill Tucker dies aged 98
-
Medicare Open Enrollment Ends Dec. 7: Review Your Coverage Options
-
Pennsylvania Democrats secure state trifecta in midterm elections
-
US Treasury order targets bank transfers linked to crypto exchange MEXC
-
Godzilla Minus Zero sets foreign-language box-office opening record
-
Nvidia CEO Controversy Sparks Fears of Tighter U.S. AI Chip Curbs for Samsung and SK hynix
-
Eagles record six sacks as rushing attack struggles against Giants
-
Villeneuve teases James Bond casting at Los Angeles museum gala
-
Thames Water seeks to delay £12bn in debt repayments
-
Nottinghamshire launches specialist rural crime policing team
-
Newark boxing gym expands alternative education programme
-
China confirms talks over possible Xi-Putin-Trump summit
-
Democrats consider impeachment drive against Defence Secretary Hegseth
-
Rail journey offers a slower route to a Berlin city break
-
Energy bill plan could use HMRC income data to target support
-
Arsenal control title race as Manchester United fall into bottom three
-
Business owner earning £6,000 a month tackles £70,000 debt
-
Suspected Krakow gunman dies after attack that killed six
-
Nvidia chief faces inquiry after disclosing affair with suspected Chinese agent
-
Carrick backs Dalot after hostile reception from Manchester United fans
-
Comet returns as online electrical marketplace 14 years after collapse
Welcome to DEA Judge McLooney's Marijuana Kangaroo Court-DEA Grants Itself a Favor, Denies MMJ Cannabis Drug Relief
While Patients Suffer, DEA Manipulates Due Process to Cover Its Cannabis Crimes. The DEA blocking federally compliant pharmaceutical research is not just bureaucratic incompetence; it is systemic negligence bordering on malpractice.
WASHINGTON, D.C. / ACCESS Newswire / July 15, 2025 / In a move that underscores everything wrong with the Drug Enforcement Administration's rogue administrative machinery, Chief Administrative Law Judge John J. Mulrooney II-dubbed "Judge McLooney" by critics-has granted the DEA government counsel's request for extra time to respond to MMJ BioPharma Cultivation's legal exceptions.
The problem? MMJ was denied a similar extension just weeks earlier. Welcome to DEA's version of justice , where the rules are rewritten on the fly- but only when it benefits the government.
The Double Standard Is Blinding
MMJ BioPharma, a pharmaceutical company developing FDA-approved cannabis medicines for Multiple Sclerosis and Huntington's Disease, filed formal exceptions on July 3, 2025. These exceptions laid out a comprehensive challenge to the agency's unlawful delay, retroactive rule changes , and structurally biased adjudication system.
On the same day, the DEA asked for time to respond-and in classic inside job fashion, Judge Mulrooney approved it with a smile.

The DEA prosecutes, adjudicates, and decides its own cases .
Parties like MMJ are trapped in legal limbo for nearly seven years .
And when a registrant finally gets its day in court, the outcome is pre-determined .
"No Undue Prejudice"-Unless You're the DEA
Mulrooney's ruling attempts to justify the favoritism, claiming that the government won't "unduly prejudice" MMJ by getting extra time. Yet just weeks ago, MMJ was denied a similar request -a blatant violation of equal treatment under the law .
"This is a kangaroo court in a lab coat," said one legal analyst. "The DEA's internal ALJ process has all the fairness of a Soviet tribunal with the constitutional legitimacy of a carnival ride."
MMJ's Exceptions: A Bombshell Legal Indictment
Filed by Megan E. Sheehan, Esq. , MMJ's legal brief outlines four devastating points:
DEA's 5-Year Delay Violates Federal Statute
Under 21 U.S.C. § 823(j) and the 2022 Medical Marijuana and Cannabidiol Research Expansion Act , DEA had 60-90 days to act. Instead, it waited nearly 5 years .Retroactive Rulemaking is a Due Process Violation
MMJ's application was submitted before the "Bona Fide Supply Agreement" rule existed. Applying it retroactively created a legal Catch-22 where compliance was impossible.DEA's ALJ Process Is Structurally Unconstitutional
MMJ cites Axon v. FTC (2023) and Free Enterprise Fund v. PCAOB , arguing that DEA's ALJs are unlawfully insulated from removal and operate under an executive echo chamber .Public Interest is Being Crushed
MMJ holds FDA INDs and Orphan Drug Designation for devastating conditions. The DEA's sabotage delays critical therapies for patients who have no other hope.
It's Not Just About MMJ-It's About the Rule of Law
This is more than a regulatory dispute. It's a crisis in American administrative law:
A federal agency is violating binding Supreme Court precedent.
A regulated entity with FDA backing is being strangled by delay and deception.
And the DEA continues to block life-saving research while allowing contaminated, cartel-grown marijuana to flourish in state markets.
Enough is Enough: The Time for Reform is Now
Congress must step in. The DEA has proven time and again that it cannot regulate fairly, legally, or scientifically.
Demand the following:
Immediate granting of MMJ's DEA license
Transfer of cannabis research oversight to the FDA or NIH
Congressional hearings on the DEA's misconduct and ALJ abuses
Full accountability for Thomas Prevoznik and the Diversion Control Division
"When the DEA denies one party an extension but grants it to its own team, you no longer have an impartial courtroom-you have a farce in a black robe," said Duane Boise, CEO of MMJ BioPharma. "It's not just a clown show-it's a taxpayer-funded sabotage of patients, science, and justice."
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
Th.Berger--AMWN